Search Results for “Pfizer” – Page 15 – media

Pfizer Receives FDA Approval for SUTENT® (sunitinib malate) as First and Only Adjuvant Treatment for Adult Patients

Pfizer Inc. (PFE) announced that the U.S. Food and Drug Administration(FDA) has approved a new indication expanding the use of SUTENT® (sunitinib malate) to include the adjuvant treatment of adult patients at high risk of recurrent renal cell carcinoma (RCC) following nephrectomy (surgical removal of the cancerous kidney). The approval was based on results from the S-TRAC trial that demonstrated a significant reduction in the risk of a disease-free survival (DFS) event (defined as the interval between randomization and tumor recurrence, or secondary primary cancer or death from any cause) for patients at high risk of RCC recurrence who received SUTENT compared to placebo in the adjuvant setting.
- Source: finance.yahoo
- 496
- November 20, 2017
DFS FDA nephrectomy RCC SUTENT
Merck, Pfizer launch Bavencio for rare skin cancer

Merck and Pfizer have launched in the UK of Bavencio, the first medicine to be licensed for the treatment of the rare, aggressive skin cancer of metastatic Merkel Cell Carcinoma (mMCC).
- Source: Pharmatimes
- 488
- November 7, 2017
avelumab Company Insight mMCC skin cancer
Pfizer to launch consumer health sale in November

Pfizer plans to kick off an auction process for its consumer healthcare business in November, paving the way for a potential $15 billion-plus sale of the headache pill to lip balm business, sources close to the matter told Reuters.
- Source: Pharmacodia
- 624
- October 30, 2017
Consumer Healthcare Market Views pill
Pfizer Presents Full Results from Phase 2 Study of Next-Generation Investigational ALK-Inhibitor Lorlatinib in ALK-Positive and ROS1-Positive Advanced Non-Small Cell Lung Cancer

Pfizer Inc. today announced full results from the Phase 2 clinical trial of the investigational, next-generation tyrosine kinase inhibitor lorlatinib that exhibited clinically meaningful activity against lung tumors and brain metastases in a range of patients with ALK-positive and ROS1-positive advanced non-small cell lung cancer (NSCLC), including those who were heavily pretreated.
- Source: Pfizer
- 693
- October 17, 2017
Clinical Trials inhibitor Phase tyrosine kinase
Pfizer reviewing strategic alternatives for consumer healthcare business

Pfizer Inc. announced that it is reviewing strategic alternatives for its Consumer Healthcare business. A range of options will be considered, including a full or partial separation of the Consumer Healthcare business from Pfizer through a spin-off, sale or other transaction, and Pfizer may ultimately determine to retain the business. Today’s announcement is part of Pfizer’s continuing efforts to allocate resources and capital to best serve patients and maximize value for its shareholders.
- Source: Pfizer
- 527
- October 13, 2017
Company Insight Consumer Healthcare strategic
Pfizer unloads Colorado plant as it continues to hive off unwanted Hospira operations

Pfizer has sold another Hospira plant, its second in eight weeks, as it continues to whittle down the unwanted operations it picked up in its $15 billion buyout of the sterile drug manufacturer.
- Source: Fiercepharm
- 503
- October 12, 2017
API Company Insight Hospira
Pfizer launches upstart with $103M, phase 3-ready drugs

In a first for the Big Pharma and as part of a new model, Pfizer is taking drugs from its shelves and licensing them to, while investing in, its SpringWorks Therapeutics startup.
- Source: Fiercebiotech
- 574
- September 27, 2017
Clinical Trials Pfizer Series
Pfizer sues Johnson & Johnson, alleging anticompetitive practices to maintain a drug monopoly

A legal brawl between two of the world’s largest drug companies could shape the future of a nascent market of copycat drugs that are intended to bring down the cost of the most advanced and expensive medicines.
- Source: Washingtonpost
- 702
- September 22, 2017
biosimilar Johnson & Johnson Pfizer rheumatoid arthritis
FDA sends damning warning letter to Pfizer after misfiring EpiPens linked to deaths

The US Food and Drug Administration(FDA) has sent a damning warning letter to drug giant Pfizer Inc (NYSE:PFE) after it received “hundreds of complaints” that the anti-allergy EpiPen device misfired “during life-threatening emergencies”.
- Source: Proactiveinvestors
- 698
- September 11, 2017
anti-allergy FDA
US regulators wave through Pfizer’s leukaemia drug

Pfizer’s Besponsa has been approved by the US Food and Drug Administration (FDA). It's the first and only CD22-directed antibody-drug conjugate indicated to treat relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL).
- Source: pharmatimes
- 1,044
- August 21, 2017
ALL antibody Company Insight FDA New Approvals

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.